G. Dave Singh DMD PhD DDSc

Bio

Dr Dave Singh is a US citizen who was born, educated and trained in England, UK. He holds three doctorates, including Doctor of Dental Medicine; a Ph.D. in craniofacial cleft palate development; and a third Doctorate in Orthodontics. Currently, Dr Singh is an Adjunct Professor in Sleep Medicine at Stanford University, USA. Previously, he was awarded a postgraduate grant (University of Oxford, UK) and was later appointed to the Board of Examiners, Royal College of Surgeons of England. Supported by Harvard University, the University of Michigan, and the University of Hawaii, he was invited to relocate to the Center for Craniofacial Disorders, University of Puerto Rico, USA where he led a NIH-funded program of clinical craniofacial research. He is an honorary diplomate of the American Sleep and Breathing Academy, a Member of the World Sleep Society, a Member of the American Academy of Sleep Medicine, a Member of the World Dentofacial Sleep Society, a Member of the NC Academy of Sleep Medicine, a Fellow of the Pierre Fauchard Academy, an Academic Fellow of the World Federation of Orthodontists, and a Fellow of the International Association for Orthodontics, where he was awarded prizes in 2005, 2013 and 2014. He has published over 220 articles in the peer-reviewed medical, dental and orthodontic literature, has published 9 books/chapters and has had over 20 US, Canadian, European and international patents issued. During 2008-2016, Dr Singh was the Founder and CEO of his start-up company, which was successfully listed on NASDAQ after its IPO in 2020. In 2019, Dr. Singh was the recipient of the US Invisible Disabilities Association award. In 2020, Dr Singh was given a lifetime achievement award for his work on obstructive sleep apnea. Dr Singh is the inventor of the DNA appliance, which was the first palatal expander to be FDA approved in 2023 for the treatment of mild-moderate as well as severe obstructive sleep apnea in adults. In 2024, the DNA appliance became the first palatal expander to be FDA approved for the treatment of obstructive sleep apnea in children